{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-26-000003","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.279495+00:00","generated_at":"2026-05-16T11:23:53.952389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch","bullets":["Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.","Over 6,500 unique eye care professionals prescribed VIZZ; more than 55% prescribed multiple times in Q4.","VIZZ launched October 2025; broad retail and epharmacy access achieved by mid-November 2025.","Announced fourth international commercialization partnership with Lunatus for Middle East with milestones and revenue share."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-26-000003","json":"https://secwatch.observer/filing/0001815776-26-000003.json","markdown":"https://secwatch.observer/filing/0001815776-26-000003.md","text":"https://secwatch.observer/filing/0001815776-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/0001815776-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/lenz-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:23:53.952389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}